Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.59 USD | -1.67% | +1.72% | -11.14% |
Business Summary
Number of employees: 67
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 14 | 100.0 % | 16 | 100.0 % | +11.66% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Lucinda Quan
FOU | Founder | 51 | 18-02-04 |
Lawrence Blatt
CEO | Chief Executive Officer | 62 | 18-02-04 |
Lesley Calhoun
DFI | Director of Finance/CFO | 58 | 20-05-31 |
Julian Symons
CTO | Chief Tech/Sci/R&D Officer | 63 | 18-04-30 |
Jordyn Tarazi
IRC | Investor Relations Contact | - | Feb. 12 |
Human Resources Officer | - | - | |
Corporate Officer/Principal | 58 | 18-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Lawrence Blatt
CEO | Chief Executive Officer | 62 | 18-02-04 |
Director/Board Member | 62 | 18-07-31 | |
K. Hirth
BRD | Director/Board Member | 72 | 18-07-31 |
Jim Scopa
BRD | Director/Board Member | 65 | 21-04-26 |
Bridget Martell
BRD | Director/Board Member | 58 | 21-11-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 3,092,338 | 0 | 0 | 76.28 % |
Stock B | 1 | 75,017,589 | 59,584,137 ( 79.43 %) | 0 |
Company contact information
Aligos Therapeutics, Inc.
1 Corporate Drive 2nd floor
94080, South San Francisco
+800 466 6059
http://www.aligos.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.14% | 46.08M | |
+43.36% | 54.64B | |
-5.31% | 39.92B | |
+37.52% | 38.82B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B |
- Stock Market
- Equities
- ALGS Stock
- Company Aligos Therapeutics, Inc.